We have investigated the difference in gene expression of six proteins secreted by adipocytes in paired biopsies from visceral and abdominal subcutaneous adipose tissue in nine individuals with various degrees of obesity. The mRNAs levels of leptin, TNFK, angiotensinogen, acylation stimulating protein (ASP), cholesterol ester transfer protein (CETP) and phospholipid transfer protein (PLTP) were quantified by RT-competitive PCR. ASP and angiotensinogen mRNA levels were higher in the visceral fat, whereas the mRNA levels of leptin and CETP were higher in the subcutaneous depot. TNFK mRNA expression was similar in the two sites. For angiotensinogen, the difference was more pronounced in the subjects with body mass index (BMI) lower than 30 kg/m 2 whereas for ASP, CETP and leptin, the difference was observed regardless the BMI of the subjects. PLTP mRNA levels in subcutaneous, but not in the visceral, adipose tissue were positively related to the BMI of the subjects. These results strongly suggest that visceral and subcutaneous adipocytes may have different properties in the production of bioactive molecules. ß
Introduction
Subjects with accumulation of visceral fat are at a higher risk for the development of obesity-related metabolic derangements, such as type-2 diabetes, car-diovascular disease, hypertension and hyperlipidemia [1^3] . The molecular basis of this association between intra-abdominal obesity and health problems is still largely unknown. Di¡erent properties between adipocytes from the intra-abdominal or the subcutaneous depots have been reported, especially regarding the control of lipolysis [4, 5] . In addition, because adipocytes are now regarded as endocrine-like cells, capable of secreting several molecules and hormones [6, 7] , depot-related di¡erences in the production of some of them could participate in the disorders linked to visceral obesity. This concept was recently reenforced with the demonstration that visceral adipocytes express and produce more plasminogen-activator inhibitor 1 (PAI-1) than subcutaneous cells [8, 9] . Among the numerous adipocyte-derived products identi¢ed so far, some play a role in the regulation of the fat mass and the control of adipocyte di¡erentiation [6, 7, 10] . Others are involved in the control of lipid and cholesterol metabolisms [11, 12] . Some of them also participate in the immune system [13, 14] and in the regulation of the blood £ow and vascular functions [15^17] . With regard to their multiple biological functions, it is likely that they participate in the metabolic consequences of obesity, such as altered lipid metabolism, insulin resistance and cardiovascular complications. It is therefore important to verify whether adipose tissue depot-speci¢c di¡erences exist in the expression and production of these factors in humans.
In the present study, we have evaluated the gene expression of several of these proteins in paired omental and abdominal subcutaneous adipose tissue biopsies from subjects spanning a wide range of body mass index (BMI). Due to the small size of the tissue samples and to the very low yields in total RNA from adipose tissue, we have elaborated a multispe-ci¢c competitor cDNA construct for the quanti¢cation by reverse transcription-competitive polymerase chain reaction (RT-cPCR) assay [18] of mRNAs encoding adipocyte-secreted proteins. We have investigated the fat depot-related di¡erence in mRNA expression of acylation stimulating protein (ASP), cholesterol ester transfer protein (CETP) and phospholipid transfer protein (PLTP), three major determinants of lipid and lipoprotein metabolism, leptin and tumor necrosis factor K (TNFK), two cytokines that participate in the control of the fat mass and potentially in the development of insulin-resistance, and angiotensinogen, a possible contributor to the obesity-related cardiovascular risk.
Materials and methods

Subjects and tissue sampling
Abdominal subcutaneous and visceral (omental) adipose tissue biopsies were obtained from nine patients (¢ve women, four men) during elective open abdominal surgery. Patients with a previous history of coronary heart disease (angina pectoris or myocardial infarction) were excluded from the study.
None of the subjects su¡ered from severe systemic illness, diabetes mellitus or other diseases known to interfere with lipid metabolism. Their age ranged from 30 to 66 years (mean þ S.E.M. = 42 þ 5 years) and all had a stable body weight for at least 3 months (BMI ranging from 18 to 58 kg/m 2 , mean = 34 þ 4 kg/ m 2 ). Tissue samples were immediately frozen in liquid nitrogen and stored at 380³C until total RNA preparation. All patients gave their written informed consent, and the project was approved by the ethics committee of Hospice Civil de Lyon.
Total RNA preparation and target mRNA quanti¢cation
Adipose tissue total RNA was prepared using the RNeasy total RNA kit (Qiagen, Courtaboeuf, France). RNA samples were quanti¢ed by spectrophotometry and the absorption ratios at 260 to at 280 nm were between 1.8 and 2.0. Average yields were similar in samples from subcutaneous (1.2 þ 0.2 Wg of total RNA/100 mg of tissue) and omental adipose tissue (1.4 þ 0.2 Wg/100 mg of tissue). Total RNA samples were diluted in water and stored at 380³C until use.
The concentration of the di¡erent mRNAs was determined by an RT-cPCR assay that consists, after a speci¢c reverse transcription reaction, of the co-ampli¢cation of the target single-strand cDNA with known amounts of a DNA competitor molecule added in the same PCR tube [18] . We have developed a multispeci¢c competitor DNA to quantify the levels of the mRNAs encoding ASP, CETP, PLTP, LPL, angiotensinogen, PAI-1, leptin, TNFK and L-actin (see after for details of the construction). For the assay of the target mRNAs, speci¢c reverse transcription reactions were performed from 0.1 or 0.2 Wg of tissue total RNA with 2.5 U of thermostable reverse transcriptase (Tth, Promega, Charbonie ©res, France) and in the presence of 15 pmol of one of the speci¢c antisense primer. The conditions required to obtain the transformation of all the target mRNA molecules into single strand cDNA during the reverse transcription reaction have been described in detail previously [18] . For cPCR ampli¢cation, the reverse transcription medium was added to a PCR master mix (10 mM Tris-HCl pH 8.3, 100 mM KCl, 0.75 mM EGTA, 5% glycerol) con-taining 0.2 mM deoxynucleoside triphosphates, 5 U of Taq polymerase (Life Technologies, Cergy Pontoise, France), 30 pmol of the speci¢c antisense primer and 45 pmol of the speci¢c sense primer. The sense primers were 5P-labelled with the CY-5 £uorescent dye (Eurogentec, Seraing, Belgium). The ¢nal volume was 100 Wl and four aliquots of 20 Wl were transferred to 0.5-ml microtubes containing 5 Wl of a de¢ned working solution of the DNA competitor. After 120 s at 94³C, the PCR mixtures were subjected to 40 cycles of PCR ampli¢cation with a cycle pro¢le including denaturation for 60 s at 94³C, hybridization for 60 s at 58³C and elongation for 60 s at 72³C. The PCR products were separated and analyzed in 4% polyacrylamide gel electrophoresis (6% for CETP mRNA assay) on a ALFexpress DNA sequencer (Pharmacia, Upsala, Sweden) using the Fragment Manager software (Pharmacia) [19] . The concentration of the target mRNAs was determined at the competition equivalence point as described in detail previously [18] . The absence of contamination with genomic DNA was checked by omitting reverse transcriptase in the reaction. To ensure that the difference in mRNA levels between paired subcutaneous and visceral adipose tissue samples were not due to subtle methodological di¡erences, total RNA were always prepared simultaneously from the two biopsies of the same subject and target mRNAs were measured in the same run of PCR, with the same dilutions of competitor. Fig. 1 depicted the organization of the homologous multispeci¢c competitor DNA (as de¢ned in [18] ) that was used to quantify the target mRNAs. First, we have constructed the nine speci¢c competitors individually. A cDNA fragment of each target mRNA was obtained by RT-PCR from human adipose tissue using the speci¢c sense and antisense primers ( Table 1 ) and high-¢delity pfu DNA polymerase (Stratagen, La Jolla, CA). Each fragment was subcloned (pGEM-T Vector System, Promega) and used to generate a speci¢c competitor either by restriction enzyme digestion and ligation (for ASP, PLTP, LPL, leptin, TNFK and L-actin) or by a PCR-based deletion/mutagenesis method [20] (for CETP, angiotensinogen and PAI-1). Each competi-tor gave rise to a PCR product that was slightly shorter in size than the normal cDNA (Table 1) . To generate the complete molecule, individual competitor cDNAs were associated together (lep-tin+LPL, CETP+ASP+angiotensinogen, PLTP+L-actin+TNFK, PAI-1) using a PCR overlap extension method [20] and high-¢delity pfu DNA polymerase. The four fragments were then subcloned successively in the same plasmid (pGEM) to obtain the full length (2969 bp) multispeci¢c homologous competitor ( Fig. 1 ). Its sequence, veri¢ed by automatic DNA sequencing, matched perfectly the target mRNA sequences reported in GenBank. The plasmid was further puri¢ed, carefully quanti¢ed and stored at 320³C. Working solutions of the competitor plasmid (20 amol/Wl to 10 33 amol/Wl) were prepared by serial dilutions in 10 mM Tris-HCl (pH 8.3), 1 mM EDTA bu¡er.
Construction of the competitor
To validate the assays, nine RNAs corresponding to part of the target mRNAs were synthetised by in vitro transcription (Riboprobe system, Promega) using the plasmids containing the cDNA fragments initially obtained by RT-PCR and subcloned in pGEM (see before). Known amounts of these RNAs (0.1^50 amol added into the RT medium) were measured by RT-cPCR to generate dose^response curves that were all linear demonstrating that the assays were really quantitative. The coe¤cient of variation of the di¡erent assays was between 9 and 18% when a given mRNA was measured several times in the same tissue sample. The validations of the RT-cPCR-based assays have been reported in detail in a methodological paper [18] .
Presentation of the results
Absolute mRNA levels were determined and presented as amol/Wg of total RNA. Data are shown as means þ S.E.M. Because we have previously examined the expression of LPL in the two fat depots [21] , we did not measured LPL mRNA in the present study. Moreover, due to the low amounts of total RNA obtained with some biopsies and because depot-related di¡erence in its expression has been already reported [8, 9] , we also did not investigate the expression of PAI-1 mRNA in this study. The di¡erences between omental and subcutaneous mRNA levels were compared using a non-parametric Wil-coxon test for paired values. The correlations between BMI and mRNA levels (or mRNA level ratio) were examined using the non-parametric Spearman's rank correlation coe¤cient. The threshold for signi¢cance was set at P 6 0.05.
Results
The sequences of the di¡erent primers used for the RT-cPCR and the sizes of the target and competitor PCR products that are generated during the reactions are presented in Table 1 . All the target mRNAs can be properly ampli¢ed from 0.1 or 0.2 Wg of total RNA from human adipose tissue (data not shown). Fig. 2 shows the absolute mRNA levels (expressed as amol/Wg of total RNA) determined in abdominal subcutaneous and visceral fat depots. Large di¡erences in the expression levels of the target mRNAs were observed in human adipose tissue. ASP mRNA was abundantly expressed, PLTP and leptin mRNAs were at intermediary levels whereas CETP, angiotensinogen and TNFK transcripts were expressed at extremely low levels (Fig. 2) . The mRNA encoding L-actin was measured to verify the integrity of the total RNA preparations. As compared with the other mRNAs of interest, L-actin was expressed at high levels both in subcutaneous and visceral fat.
The mRNA levels of ASP and angiotensinogen were signi¢cantly higher in the visceral adipose tissue (P = 0.03 for ASP and P = 0.01 for angiotensinogen mRNA, respectively). On the opposite, leptin (P = 0.02) and CETP (P = 0.01) mRNAs were more expressed in the subcutaneous adipose tissue (Fig. 2) .
The average values of PLTP and TNFK mRNA levels were similar in subcutaneous and in visceral adipose tissue (Fig. 2) . Because of the low number of subjects, and to ensure that the di¡erences were real and not due to chance ¢ndings, we determined the statistical power of the analyses. We found values higher than 80% for leptin, CETP and angiotensinogen and of 65% for ASP, indicating thus that the results likely correspond to real di¡erences. For ASP, leptin and CETP mRNAs, the depot-related di¡erence was found in almost all subjects, regardless of their BMI (Fig. 3) . For angiotensinogen mRNA, a Fig. 1 . Organization of the multispeci¢c competitor. The nine homologous competitors were constructed individually and cloned in the pGEM plasmid vector to generate the full length (2969 bp) multispeci¢c competitor, as described in Section 2. The arrows indicate the position and orientation of the sense (S) and antisense (AS) primers for each target (see Table 1 for their sequences). The number of nucleotides that was deleted from the normal cDNA sequences is indicated in brackets. marked depot-related di¡erence was found in the four subjects with BMI lower than 30 kg/m 2 . These latter had an about 4-fold higher level of angiotensinogen mRNA in the visceral as compared to the subcutaneous fat depot (Fig. 3 ). Regarding PLTP mRNA expression, there was no depot-related di¡erence when the mean level values were considered (Fig. 2 ). However, there was a negative correlation between the visceral to subcutaneous ratio of PLTP mRNA and the BMI of the subjects (Fig. 3 ). Finally, there was no depot-related di¡erence in the mRNA levels of TNFK, either in lean or in obese subjects ( Figs. 2 and 3 ).
We further analyzed the possible relationships be-tween the target mRNA expression levels in the two fat depots and the degree of obesity of the subjects ( Table 2 ). Leptin mRNA levels were positively correlated with the BMI of the subjects both in the subcutaneous and the visceral depots. Similar results were found with TNFK mRNA levels. Angiotensinogen mRNA levels correlated positively with the BMI in the subcutaneous but not in the visceral adipose tissue. Similarly, a signi¢cant positive correlation was found between PLTP mRNA levels and the BMI in the subcutaneous but not in the visceral depot. Interestingly, PLTP mRNA levels in the subcutaneous adipose tissue was also associated with the waist to hip circumference ratio of the subjects (r = 0.956, The location of the primers on the coding sequences of the target mRNAs is indicated by indexed numbers. The GenBank accession numbers of the nine targets are indicated in brackets. The target mRNAs and the competitors generated PCR products of di¡erent sizes allowing their separation on polyacrylamide gel electrophoresis. The sense primers were 5P-end labeled with the £uorescent dye CY-5 for analysis on an automated £uorescence DNA sequencer. Despite a tendency for leptin (r = 0.666, P = 0.08) and for TNFK (r = 0.633, P = 0.07) mRNAs, there was no signi¢cant correlation between the mRNA levels in the subcutaneous fat and the mRNA levels in the visceral adipose tissue for any of the target genes.
Discussion
To investigate whether the gene expression of im-portant proteins secreted by adipocytes di¡ers between visceral and subcutaneous human adipose tissue depots, the mRNAs levels of ASP, PLTP, leptin, CETP, TNFK and angiotensinogen were quanti¢ed by RT-cPCR in paired biopsies from individuals with various degrees of obesity. In agreement with previous reports, leptin mRNA was found to be more expressed in subcutaneous than in omental fat [212 3]. We also con¢rmed the lack of depot-related difference in the mRNA expression of TNFK in human adipose tissue [24] . On the other hand, our study demonstrated, for the ¢rst time, that mRNA expressions of ASP, angiotensinogen, CETP and PLTP are di¡erent in intra-abdominal compared to subcutaneous adipose tissues in humans.
Depot-related di¡erences in the metabolic functions of adipocytes have already been reported and suggested to participate in the link between visceral fat accumulation and a higher risk for cardiovascular disease and other obesity-related outcomes [1] . Visceral adipocytes are less responsive to the anti-lipolytic action of insulin and more responsive to the lipolytic action of catecholamines [4, 5] . These metabolic di¡erences are not related to di¡erences in the expression levels of the genes coding either key enzymes of triacylglycerol hydrolysis [21, 24] or the main steps of insulin action [21] . Therefore, the increased lipolytic rates of omental adipocytes are most Fig. 3 . Relationship between BMI and the relative mRNA levels of the target genes in visceral versus subcutaneous adipose tissue biopsies. probably due to di¡erences in the hormonal control of the metabolic pathway, as previously discussed [21] . In addition to this metabolic aspect, adipocytes are now known to secrete several bioactive molecules that may be involved in lipid metabolism, cardiovascular functions and insulin resistance [7^17, 25] . Therefore, the ¢nding that some of these molecules are expressed di¡erently in visceral and in subcutaneous adipose tissue sheds new additional light on the possible molecular link between intra-abdominal fat accumulation and obesity-related metabolic diseases. However, because we reported data at the mRNA levels only, further studies are now needed to verify whether the protein levels and their secretion rates are also di¡erent between fat depots. TNFK produced by adipose tissue is regarded as a possible mediator of insulin resistance [25] and its expression is increased in subcutaneous adipose tissue of obese subjects [26, 27] . We found that the correlation between TNFK mRNA levels and the BMI of the subjects is also present in the visceral adipose tissue. However, the expression levels of TNFK in human fat tissues are extremely low ( [24] , this study), and therefore the contribution of adipose tissue to the circulating levels of TNFK is questionable. It was recently demonstrated using arteriovenous balance technique that the subcutaneous adipose tissue do not release measurable amount of TNFK protein into the circulation in lean and in obese subjects [13] . Our data indicated that a greater contribution of the visceral fat is unlikely because there is no di¡erence in the expression of TNFK mRNA between visceral and subcutaneous depots.
We found that angiotensinogen mRNA levels are higher in visceral fat, particularly in individuals with BMI lower than 30 kg/m 2 in whom a more than 4fold di¡erence was observed between omental and subcutaneous mRNA abundances. In the more obese subjects, this di¡erence was less apparent, mainly due to signi¢cantly increased expression of angiotensinogen in subcutaneous adipose tissue without a change in its expression in the visceral fat. Angiotensinogen is the precursor of angiotensin II, an important regulator of blood pressure and of salt and water balance. Interestingly, angiotensin II can also participate in the regulation of adipocyte di¡erentiation [28] . The mRNA expression of angiotensinogen, as well as of the enzymes required for its conversion into angiotensin II, has been already reported in human adipose tissue [15, 16] . Our study demonstrates that there is an increased expression of angiotensinogen in abdominal subcutaneous adipose tissue in obese subjects. The observed depot-related di¡erence in angiotensinogen expression might therefore be of importance in the regulation of adipogenesis and in the development of diseases secondary to fat accumulation, such as hypertension.
ASP has been proposed to be a major determinant of the rate of triglyceride synthesis in adipocytes (see [29] for review). ASP is a 77 amino-acid long peptide derived from the third component of the complement (C3a) by interactions of the proteins of the alternative complement pathway factor B, factor D and C3 [29] . These three proteins are all produced by adipocytes [11, 30] . Since ASP is generated by post-translational modi¢cation of the protein C3a (removal of the carboxy-terminal arginine), the RT-cPCR assay developed in the present work is speci¢c for the mRNA encoding the fragment C3a of the C3 gene [31] . Therefore, if the post-translational modi¢cations are limiting steps in the production of ASP, the measured ASP/C3a mRNA levels might not estimate correctly the expression of the ASP protein.
Nevertheless, our results showed that ASP/C3a mRNA is expressed at very high levels in human adipose tissue. The abundance of ASP/C3a mRNA is about two-fold higher in visceral adipose tissue as compared with abdominal subcutaneous fat. If this di¡erence is re£ected at the protein level, a higher local production of ASP in omental fat should result in increased rates of fatty acid uptake and reesteri¢cation. However, this seems not to be the case since omental adipocytes have been shown to be characterized by a greater lipolytic rate and reduced responsiveness to insulin [4] . It may be possible that ASP/ C3a gene expression is increased in omental fat as a compensatory phenomenon to counteract the greater lipolytic capacity of the visceral cells.
Obesity, and predominantly intra-abdominal fat accumulation, is usually associated with major abnormalities in lipoprotein pro¢le [1, 3] . Movements of neutral lipids and phospholipids between the different plasma lipoproteins involve the action of the lipid transfer proteins CETP and PLTP (see [32] for review). CETP mediates the net transfer of cholesterol ester and its exchange with triglycerides from HDL to VLDL, and PLTP possesses a phospholipid transfer activity from VLDL to HDL as well as an HDL conversion activity [32] . CETP mRNA expression has already been demonstrated in human adipocytes and is related to the membrane cholesterol content of the cells [12] . In addition, a recent report suggested that adipose tissue production may contribute to the plasma concentration of CETP protein [33] . Plasma CETP protein mass and activity are increased in obese subjects [34] ; however, we did not ¢nd correlation between CETP mRNA expression in adipose tissue and the BMI of the subjects. Subcutaneous adipose tissue level of CETP mRNA is about two-fold higher than the expression in visceral fat, regardless of the degree of obesity of the subjects. Interestingly, subcutaneous adipocytes have been shown to possess higher cholesterol content and HDL binding capacities than omental fat cells [35] . The greater expression of CETP in subcutaneous adipose tissue may therefore participate in this depot-speci¢c di¡erence in cholesterol metabolism. Alternatively, however, the di¡erence in cholesterol metabolism in the two fat depots may in£uence the expression of CETP gene.
Contrary to CETP, PLTP expression has never been reported in human adipose tissue. In this study, we demonstrated that PLTP mRNA is actually expressed at relatively high level both in subcutaneous and in visceral adipose tissue. The average PLTP mRNA levels were similar to those found for leptin mRNA in obese subjects. These results suggest thus that adipose tissue may contribute to the plasma level of PLTP. In addition, a signi¢cant depot-related di¡erence in PLTP mRNA expression was observed, particularly in lean subjects. The greater expression of PLTP mRNA observed in the visceral fat in lean subjects was compensated, in obese subjects, by an increased levels of PLTP mRNA in subcutaneous adipose tissue. Recently, plasma PLTP activity has been related to insulin resistance and to alterations in HDL metabolism in obese type-2 diabetic patients [36] . The same group has also demonstrated that plasma PLTP activity was positively related to the BMI, the waist to hip circumference ratio and fasting blood glucose in obese non-diabetic men [37] . In view of the high level of PLTP mRNA expression in human adipose tissue and of its correlations with the BMI and the waist to hip ratio of the subjects, it will be important to verify to which extent adipose tissuederived PLTP is involved in the regulation of HDL metabolism and whether or not it plays a role in the insulin resistance syndrome.
In summary, human adipose tissue presents significant depot-speci¢c di¡erences in the mRNA expression levels of several important proteins with bioactive functions. Abdominal subcutaneous adipose tissue displays a greater expression of leptin and CETP mRNAs, whereas omental adipose tissue is characterized by higher levels of ASP, angiotensinogen and PLTP mRNAs, particularly in subjects with BMI lower than 30 kg/m 2 . It is now important to verify whether the secretion rates of these factors are also di¡erent between the fat depots in order to de¢ne new molecular links between adipose tissue distribution and the metabolic derangements associated with obesity.
